|
Monday, June 14, 2010
Embassy Suites, Chesterbrook, Pennsylvania (directions)
|
Immunomic Therapeutics, Inc.
Clinical stage biotechnology company
About
|
Immunomic Therapeutics, Inc. (ITI) is a clinical stage biotechnology company with exceptional patented science for application to vaccines and vaccine immunotherapy. The Company’s core technology, LAMP-vax™, significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. LAMP vaccines have been validated in humans including the cancer vaccine, GRNVAC1, which was recently reported to reach its preliminary Phase II endpoints for safety and show promising efficacy results.
3 Major Issues
|
- Technology: Our products are based on a DNA vaccine platform which has struggled to get through the FDA for human applications. We believe that we have addressed the major issues in application of the technology through intelligent selection of our product area (allergy) and through correct clinical trials design which are all enhanced by our patented LAMP Technology. The question is, "How do we best address the problem of the negative perceptions associated with DNA vaccines?" We see this in fund raising and grant reviews and it is a challenge for us.
- Clinical / Communications: We recently had our pre-IND meeting with the FDA and they endorsed our study plan. Working from that blueprint, we developed a budget and time-line that would enable us to complete both Phase I & Phase II in 2011 with a total cost of about $2.5 million. This time-line and budget always raises eyebrows because it seems to be too low a number and too short a time! Further, we have selected a target in Japanese Red Cedar which is well-known in the allergy community as a major market opportunity but seems odd when presented to investors. So I ask, "What format and message needs to come through to get maximum credibility for this very smart clinical trials design? What types of data and information will make clear the competitive advantage we have in the clinic?"
- Business / IP Management: We have created an IP Management Committee to get a full understanding of not only our own IP, but the landscape of the vaccine world. The waters were further muddied by the recent court decision ruling against the patenting of genes. What is the thinking of the team on the value of a company's IP portfolio particularly with respect to the very large cost of building new patents and maintaining existing ones? Is there some general guidelines on how much a young company should allocate to its patent portfolio?
Program:
|
6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
8:00 - Bill Hearl, CEO of Immunomix will deliver the Company's "Elevator" Pitch to the Group
8:20 - A Panel will address 3 Major Issues for the Company
9:00 - Open discussion: members and guests
<Top of the page>
|
 |
|
 Slides
None available at this time
 Audio
None available at this time
 Video
None available at this time
 Webcast
None available at this time
|
|
|
